Comparing effectiveness of Centchroman and Tamoxifen in mastalgia: a randomised control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030206

Enrollment

Registered

2021-01-04

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R52- Pain, unspecified

Interventions

Intervention1: Centchroman: Tab Centchroman 30 mg daily for 3 months Control Intervention1: Tablet Tamoxifen 10 mg: one tablet daily for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: breast pain for more than 3 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
breast painTimepoint: 1month, 2month, 3 month and 6th month	—

Secondary

Measure	Time frame
Recurrence of SymptomsTimepoint: 6 months	—

Countries

India

Contacts

Public ContactMithilesh Kumar Sinha

AIIMS Bhubaneswar

mks132@gmail.com09438884252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026